

To
The General Manager
BSE Limited
Corporate Relation Department
Phiroze Jeejeeboy Towers, 14th Floor,
Dalal Street, Fort, Mumbai- 400 001
Scrip Code: 524731

Dear Sir/Madam,

Subject: Prior intimation of meeting of Buyback Committee of the Board of Directors of the Jenburkt Pharmaceuticals Limited (“Company”) to consider closure of the Buyback.

We refer to our letter no. JPL/CS/1835/2023, dated 01st December, 2022, submitted to the exchange disclosing the outcome of the meeting of the board of directors of the Company, held on 01st December, 2022, wherein the Board approved the buyback by the Company of its fully paid equity shares of face value of ₹10 each (“Equity Share”) from the shareholders of the Company excluding promoters, promoter group and persons who are in control of the Company, via the “Open Market” route through the stock exchange mechanism, at a price not exceeding Rs. 702/- (Rupees Seven Hundred and Two only) per Equity Share (the “**Maximum Buyback Price**”) payable in cash for an aggregate amount not exceeding Rs. 11,60,00,000/- (Indian Rupees Eleven Crores Sixty Lakhs only) (the “**Maximum Buyback Size**”) (“**Buyback**”) and the Minimum Buyback size was fixed at Rs. 5,80,00,000/- (Rupees Five Crore Eighty Lakhs Only) (“**Minimum Buyback Size**”). We also refer to Public Announcement dated 03rd December, 2022 made by the Company and published on 05th December, 2022, as was submitted to the Exchange vide our letter no.: JPL/CS/1839/2023 dated, 05th December, 2022 (“**Public Announcement**”).

We hereby inform the exchange that a meeting of the Buyback Committee of the Company is schedule to be held on Friday, 24th March, 2023, inter-alia, to consider the closure of the Buyback as well as matter related/ incidental thereto in accordance with the applicable provisions under the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws. We shall disseminate outcome of the said meeting, schedule on 24th March, 2023, to the exchange.

A copy of this intimation is also being made available on the Company's website at www.jenburkt.com.

You are requested to take the above information on record.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited,

Ashish R. Shah
Company Secretary & Compliance Officer.